449 related articles for article (PubMed ID: 37437051)
1. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.
Amellal H; Assaid N; Charoute H; Akarid K; Maaroufi A; Ezzikouri S; Sarih M
PLoS One; 2023; 18(7):e0288557. PubMed ID: 37437051
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients.
Assaid N; Arich S; Charoute H; Akarid K; Anouar Sadat M; Maaroufi A; Ezzikouri S; Sarih M
Am J Trop Med Hyg; 2023 Jan; 108(1):145-154. PubMed ID: 36509045
[TBL] [Abstract][Full Text] [Related]
3. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.
Servian CDP; Spadafora-Ferreira M; Dos Anjos DCC; Guilarde AO; Gomes-Junior AR; Borges MASB; Masson LC; Silva JMM; de Lima MHA; Moraes BGN; Souza SM; Xavier LE; de Oliveira DCA; Batalha-Carvalho JV; Moro AM; Bocca AL; Pfrimer IAH; Costa NL; Feres VCR; Fiaccadori FS; Souza M; Gardinassi LG; Durigon EL; Romão PRT; Jorge SAC; Coelho V; Botosso VF; Fonseca SG
Front Immunol; 2023; 14():1206979. PubMed ID: 37876932
[TBL] [Abstract][Full Text] [Related]
4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
5. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
6. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
7. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
9. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.
Woo PC; Lau SK; Wong BH; Chan KH; Chu CM; Tsoi HW; Huang Y; Peiris JS; Yuen KY
Clin Diagn Lab Immunol; 2004 Jul; 11(4):665-8. PubMed ID: 15242938
[TBL] [Abstract][Full Text] [Related]
11. Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Serwanga J; Ankunda V; Sembera J; Kato L; Oluka GK; Baine C; Odoch G; Kayiwa J; Auma BO; Jjuuko M; Nsereko C; Cotten M; Onyachi N; Muwanga M; Lutalo T; Fox J; Musenero M; Kaleebu P;
Front Immunol; 2023; 14():1152522. PubMed ID: 37006272
[TBL] [Abstract][Full Text] [Related]
12. Antibody response and risk of reinfection over 2 years among the patients with first wave of COVID-19.
Peghin M; De Martino M; Palese A; Chiappinotto S; Fonda F; Gerussi V; Sartor A; Curcio F; Grossi PA; Isola M; Tascini C
Clin Microbiol Infect; 2024 Apr; 30(4):522-530. PubMed ID: 38141821
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.
Sun B; Feng Y; Mo X; Zheng P; Wang Q; Li P; Peng P; Liu X; Chen Z; Huang H; Zhang F; Luo W; Niu X; Hu P; Wang L; Peng H; Huang Z; Feng L; Li F; Zhang F; Li F; Zhong N; Chen L
Emerg Microbes Infect; 2020 Dec; 9(1):940-948. PubMed ID: 32357808
[TBL] [Abstract][Full Text] [Related]
18. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
Front Immunol; 2021; 12():724763. PubMed ID: 34489978
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
20. Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.
Oluka GK; Namubiru P; Kato L; Ankunda V; Gombe B; Cotten M; ; Musenero M; Kaleebu P; Fox J; Serwanga J
Front Immunol; 2023; 14():1113194. PubMed ID: 36999017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
